Reata Pharmaceuticals Stock Forecast, Price & News

-0.61 (-0.47 %)
(As of 07/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume187,392 shs
Average Volume368,249 shs
Market Capitalization$4.65 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RETA News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Reata Pharmaceuticals logo

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.03 out of 5 stars

Medical Sector

244th out of 2,214 stocks

Pharmaceutical Preparations Industry

126th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

Is Reata Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Reata Pharmaceuticals stock.
View analyst ratings for Reata Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Reata Pharmaceuticals?

Wall Street analysts have given Reata Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Reata Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Reata Pharmaceuticals

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) announced its quarterly earnings results on Thursday, May, 6th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($2.18) by $0.32. The firm earned $0.94 million during the quarter, compared to analyst estimates of $1.43 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 88.44% and a negative net margin of 3,092.54%. The company's quarterly revenue was down 30.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.89) EPS.
View Reata Pharmaceuticals' earnings history

How has Reata Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Reata Pharmaceuticals' stock was trading at $157.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RETA stock has decreased by 18.9% and is now trading at $128.06.
View which stocks have been most impacted by COVID-19

What price target have analysts set for RETA?

4 equities research analysts have issued twelve-month target prices for Reata Pharmaceuticals' shares. Their forecasts range from $155.00 to $244.00. On average, they expect Reata Pharmaceuticals' stock price to reach $219.00 in the next year. This suggests a possible upside of 71.0% from the stock's current price.
View analysts' price targets for Reata Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the following people:
  • J. Warren Huff, Chairman, President & Chief Executive Officer
  • Manmeet Singh Soni, Executive VP, Chief Operating & Financial Officer
  • W. Christian Wigley, Chief Scientific Officer, SVP & Founding Scientist
  • Colin J. Meyer, Chief Research & Development Officer, Executive VP
  • Edmund Doherty, Vice President-Medical Affairs

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals CEO Warren Huff on Warren Huff has an approval rating of 92% among Reata Pharmaceuticals' employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Reata Pharmaceuticals' key competitors?

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Emerald Advisers LLC (0.68%) and Eagle Global Advisors LLC (0.09%). Company insiders that own Reata Pharmaceuticals stock include Colin John Meyer, Elaine Castellanos, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Michael D Wortley.
View institutional ownership trends for Reata Pharmaceuticals

Which institutional investors are selling Reata Pharmaceuticals stock?

RETA stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Colin John Meyer, Elaine Castellanos, James Warren Huff, and Michael D Wortley.
View insider buying and selling activity for Reata Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Reata Pharmaceuticals stock?

RETA stock was purchased by a variety of institutional investors in the last quarter, including Eagle Global Advisors LLC.
View insider buying and selling activity for Reata Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $128.06.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals has a market capitalization of $4.65 billion and generates $9.02 million in revenue each year. The company earns $-247,750,000.00 in net income (profit) each year or ($7.35) on an earnings per share basis.

How many employees does Reata Pharmaceuticals have?

Reata Pharmaceuticals employs 267 workers across the globe.

What is Reata Pharmaceuticals' official website?

The official website for Reata Pharmaceuticals is

Where are Reata Pharmaceuticals' headquarters?

Reata Pharmaceuticals is headquartered at 5320 LEGACY DRIVE, PLANO TX, 75024.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company can be reached via phone at (972) 865-2219 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.